Advertisement

Related Videos

Deborah Collyar: What's In It for Patients?

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Opening Session Panel Discussion

Varsha Gandhi, PhD, on Ibrutinib

Advertisement

Advertisement




Sep
17
Today In Oncology
What Constitutes Clinical Expertise in an AI-Enabled Era
American Cancer Society Urges Men to Understand Their Risk for Prostate Cancer
Two Phase III Trials Explore B7-H3–Directed ADCs in Relapsed SCLC
ADC/Immunotherapy Combination Shows Activity in Treatment-Resistant Nasopharyngeal Carcinoma
Long-Term Benefit Seen With Adjuvant Osimertinib in EGFR-Mutated NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo